secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001140361-25-000870
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M
------------------------------------------------------

- FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.
- FY2025 revenue guided >$485M, net income >$170M, Adj EBITDA >$220M; FY2026 revenue >$600M, net income >$230M.
- PAS submitted to FDA for yield enhancement process that could increase IG yields ~20%; approval expected mid-2025.
- Executed long-term high titer plasma supply contracts from ~250 collection centers (5x increase) to support ASCENIV growth.
- Balance sheet: net cash surplus vs. $75M debt; expect >$1B annual revenue before 2030 with outsized earnings growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125000870/0001140361-25-000870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125000870/ef20041448_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer